Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results
Xeris to Present at Oppenheimer 34th Annual Healthcare Life Science Conference
Xeris Pharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Reports Third Quarter 2023 Financial Results
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
Xeris Ships One Millionth Gvoke® Unit
US-based pharmaceutical company Xeris Biopharma has dosed the first participant in a Phase II clinical trial of subcutaneous (SC) XP-8121 injection to treat adults with hypothyroidism.